Drugs for Hypophosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 53)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Iron isomaltoside 1000 |
Approved, Investigational |
Phase 4 |
|
1370654-58-2 |
|
Synonyms:
|
2 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
3 |
|
Calcitriol |
Approved, Nutraceutical |
Phase 4 |
|
32222-06-3 |
134070 5280453 |
Synonyms:
(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1Α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
1 alpha, 25 Dihydroxy 20 epi vitamin D3
1 alpha, 25-Dihydroxy-20-epi-vitamin D3
1 alpha,25 Dihydroxycholecalciferol
1 alpha,25 Dihydroxyvitamin D3
1 alpha,25-Dihydroxycholecalciferol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxy 20 epi vitamin D3
1,25 Dihydroxycholecalciferol
1,25 Dihydroxyvitamin D3
1,25(OH)2-20epi-D3
1,25(OH)2-20EPi-D3
1,25-(OH)2D3
1,25-(OH)2-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25D3
1,25-DHCC
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-Dihydroxy-20-epi-vitamin D3
1,25-dihydroxycholecalciferol
1,25-Dihydroxycholecalciferol
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25(OH)2D3
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1a,25-Dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol
1-a-25-Dihydroxyvitamin D3
1-alpha,-1,25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1alpha,25(OH)2-D3
1alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1Α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1Α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
1Α,25-dihydroxyvitamin D3
1Α,25-dihydroxyvitamin D3 / 1α,25-dihydroxycholecalciferol / calcitriol
1-Α-25-dihydroxyvitamin D3
20 Epi 1alpha,25 dihydroxycholecaliferol
20-epi-1alpha,25-dihydroxycholecaliferol
20-Epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
Abbott brand OF calcitriol
AC-1859
AC1NQX1S
alpha,25-Dihydroxyvitamin D3, 1
Alphapharm brand OF calcitriol
Ambap32222-06-3
Asentar
BCBcMAP01_000160
BML2-E03
Bocatriol
|
BSPBio_001287
C01673
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriol abbott brand
Calcitriol alphapharm brand
Calcitriol cryopharma brand
Calcitriol galderma brand
Calcitriol gry brand
Calcitriol jenapharm brand
Calcitriol kyramed
Calcitriol kyramed brand
Calcitriol leo brand
Calcitriol medice brand
Calcitriol nefro
Calcitriol renacare brand
Calcitriol roche brand
Calcitriol-nefro
CalcitriolNefro
Calcitriolum
Calcitriolum [INN-Latin]
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Cryopharma brand OF calcitriol
D00129
D1530_SIGMA
D3, 1 alpha,25-Dihydroxyvitamin
D3, 1,25-Dihydroxy-20-epi-vitamin
D3, 1,25-Dihydroxyvitamin
Decostriol
Dihydroxyvitamin D3
DN 101
DN-101
EINECS 250-963-8
Galderma brand OF calcitriol
Gry brand OF calcitriol
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
Hoffmann la roche brand OF calcitriol
Hoffmann-la roche brand OF calcitriol
HSDB 3482
IDI1_033757
Jenapharm brand OF calcitriol
KyraMed brand OF calcitriol
KyraMed, calcitriol
Leo brand OF calcitriol
LMST03020258
LS-53093
MC1288
MC-1288
Medice brand OF calcitriol
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Osteotriol
RenaCare brand OF calcitriol
Renatriol
Ro 215535
Ro 21-5535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
Roche brand OF calcitriol
S1466_Selleck
SAM001246772
Silkis
Sitriol
SMR000466393
Soltriol
Spectrum5_002061
Tirocal
Topitriol
Toptriol
U 49562
Vectical
vit D
ZINC03924790
|
|
4 |
|
Hormones |
|
Phase 4 |
|
|
|
5 |
|
Vitamins |
|
Phase 4 |
|
|
|
6 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
7 |
|
Calciferol |
|
Phase 4 |
|
|
|
8 |
|
Nutrients |
|
Phase 4 |
|
|
|
9 |
|
Micronutrients |
|
Phase 4 |
|
|
|
10 |
|
Trace Elements |
|
Phase 4 |
|
|
|
11 |
|
Hematinics |
|
Phase 4 |
|
|
|
12 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
13 |
|
Antibodies |
|
Phase 4 |
|
|
|
14 |
|
Antibodies, Monoclonal |
|
Phase 4 |
|
|
|
15 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
16 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
17 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
18 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
19 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
20 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
21 |
|
Parathyroid hormone |
Approved, Investigational |
Phase 3 |
|
9002-64-6 |
|
Synonyms:
Parathormone
Parathormone (human recombinant)
Parathyrin
Parathyroid hormone
Parathyroid hormone (1-84) human recombinant
Parathyroid hormone (rDNA)
|
PTH
PTH(1-84)
rhPTH
rhPTH(1-84)
rPTH
rPTH(1-84)
|
|
22 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
23 |
|
Mitogens |
|
Phase 3 |
|
|
|
24 |
|
Protective Agents |
|
Phase 2 |
|
|
|
25 |
|
potassium phosphate |
|
Phase 2 |
|
|
|
26 |
|
Dextrans |
|
Phase 2 |
|
|
|
27 |
|
Plasma Substitutes |
|
Phase 2 |
|
|
|
28 |
|
Anticoagulants |
|
Phase 2 |
|
|
|
29 |
|
Blood Substitutes |
|
Phase 2 |
|
|
|
30 |
|
Iron-Dextran Complex |
|
Phase 2 |
|
|
|
31 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
Cinacalcet |
Approved |
Phase 1 |
|
226256-56-0 |
156419 |
Synonyms:
(R)-alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-a-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-N-(1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
(R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
(R)-Α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine
073, AMG
1493, KRN
226256-56-0
364782-34-3 (Hydrochloride)
AC1L4G5X
alpha-Methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphar)-hydrochloride
AMG 073
AMG073
CHEBI:48390
CID156419
Cinacalcet
Cinacalcet (USAN)
Cinacalcet [INN]
|
Cinacalcet hydrochloride
CNC
D03504
DB01012
HSDB 7318
Hydrochloride, cinacalcet
I14-3270
LS-187374
Mimpara
MolPort-003-845-954
N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine
N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
N-[(1R)-1-naphthalen-1-ylethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
NCGC00181002-01
nchembio.2007.55-comp29
Sensipar
TL8001899
UNII-UAZ6V7728S
|
|
33 |
|
Sorafenib |
Approved, Investigational |
Phase 1 |
|
284461-73-0 |
216239 406563 |
Synonyms:
284461-73-0
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafénib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
34 |
|
Protein Kinase Inhibitors |
|
Phase 1 |
|
|
|
35 |
|
Benzocaine |
Approved, Investigational |
|
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
36 |
|
tannic acid |
Approved |
|
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
37 |
|
Sevelamer |
Approved |
|
|
52757-95-6 |
|
Synonyms:
|
38 |
|
Calcium acetate |
Approved, Investigational |
Early Phase 1 |
|
62-54-4 |
|
Synonyms:
Acetate of lime
Brown acetate of lime
Calcio acetato
Calcium acetate
calcium ethanoate
|
calcium(II) acetate
Gray acetate of lime
Lime acetate
Lime pyrolignite
|
|
39 |
|
Salmon calcitonin |
Approved, Investigational |
|
|
47931-85-1 |
16129616 |
Synonyms:
135506-95-5
47931-85-1
Astronin
Biocalcin
Bionocalcin
C028815
C06865
C145H239N43O48S2
Cadens
Calciben
Calcihexal
Calcimar
Calcimar (TN)
Calcimonta
Calcinil
Calcioton
Calcitonin (Salmon Synthetic)
Calcitonin (salmon)
Calcitonin [USAN:INN:BAN:JAN]
Calcitonin salmon
Calcitonin salmon (synthesis)
Calcitonin salmon (synthesis) (JAN)
Calcitonin salmon (USAN/INN)
Calcitonin salmon recombinant
Calcitonin vom lachs
Calcitonin, salmar
Calcitonin, salmon
CALCITONIN, SALMON
Calcitonin, salmon, for bioassay
Calcitonin,salmon
Calcitonina
Calcitonina salmón sintética
Calcitonine de saumon
Calcitonin-salmon
Calcitoran
Calco
Calogen
Calsynar
Calsynar Lyo L
Caltine
Casalm
Catonin
Cibacalcin
Cibacalcine
Citonina
D00249
|
EINECS 256-342-8
Eptacalcin
Forcaltonin
Fortical
Fortical (TN)
Ipocalcin
Isi-calcin
Kalsimin
Karil
LS-48624
Miacalcic
Miacalcin
Miacalcin (TN)
Miracalcic
Oseototal
Osseocalcina
Osteobion
Osteovis
Ostosalm
Ostostabil
Porostenina
Prontocalcin
Quosten
recombinant salmon calcitonin
Recombinant salmon calcitonin
Riostin
Rulicalcin
Salcat
Salcatonin
Salcatyn
Salmocalcin
Salmofar
Salmon calcitonin
salmon calcitonin (1-32)
Salmon calcitonin I
Salmon calcitonin-(I-32)
Sical
Stalcin
Staporos
Steocin
synthetic salmon calcitonin
Thyrocalcitonin (salmon)
Tonocalcin
TZ-CT
Ucecal
UNII-7SFC6U2VI5
|
|
40 |
|
Sodium citrate |
Approved, Investigational |
|
|
68-04-2 |
|
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
|
Sodium citrate, anhydrous
Sodium citrate,anhydrous
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
41 |
|
Iron |
Approved |
|
|
7439-89-6 |
23925 29936 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
|
Fe
FE
FE (III) ion
Fe(3+)
Fe(III)
Fe1+
Fe-40
fer
Feronate
Ferretts
Ferric ion
Ferric iron
Ferro-Caps
Ferro-Time
ferrous iron
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(3+)
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
Siderol
SUY-B 2
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
|
|
42 |
|
Alfacalcidol |
Approved, Nutraceutical |
|
|
41294-56-8 |
5282181 |
Synonyms:
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1a,3b-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
(5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1α,3β-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1α,3β-diol
1 alpha-Hydroxycholecalciferol
1 alpha-Hydroxyvitamin D3
1a-Hydroxycholecalciferol
1a-Hydroxyvitamin D3
1a-Hydroxy-vitamin D3
1a-Hydroxyvitamin D3 / 1a-hydroxycholecalciferol
1alpha-hydroxycholecalciferol
1alpha-Hydroxycholecalciferol
1alpha-Hydroxyvitamin D3
1alpha-Hydroxy-vitamin D3
1alpha-OHD3
1-alpha-Oxycholecalciferol
1-hydroxycholecalciferol
1-Hydroxycholecalciferol
1-Hydroxycholecalciferol, (1alpha,3alpha-(5Z,7E))-isomer
1-Hydroxycholecalciferol, (1beta)-(5Z)-isomer
1-Hydroxycholecalciferol, (1beta,3beta-(5E,7E))-isomer
1-Hydroxycholecalciferol, aluminum salt
1α-hydroxycholecalciferol
|
1Α-hydroxycholecalciferol
1α-hydroxyvitamin D3
1α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3
1Α-hydroxy-vitamin D3
1Α-hydroxyvitamin D3 / 1α-hydroxycholecalciferol
9,10-Secocholesta-5,7,10(19)-triene-1a,3b-diol
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
9,10-secocholesta-5,7,10(19)-triene-1α,3β-diol
9,10-Secocholesta-5,7,10(19)-triene-1α,3β-diol
Alfacalcidol
Alfacalcidolum
AlfaD
Alphacalcidol
Alsiodol
Bondiol
Doss brand OF alfacalcidol
Eenalfadrie
EinsAlpha
Etalpha
Oksidevit
One-Alpha
Un-alfa
|
|
43 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
|
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-carboxy-3-hydroxypentane-1,5-dioic acid
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
|
Citrate anhydrous
Citretten
Citric acid anhydrous
Citric acid monoglyceride
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
Uro-trainer
|
|
44 |
|
Calcitonin gene-related peptide |
Investigational |
|
|
83652-28-2 |
|
Synonyms:
Calcitonin gene related peptide
Calcitonin-gene-related peptide
|
|
|
45 |
|
Hydroxycholecalciferols |
|
|
|
|
|
46 |
|
Chelating Agents |
|
Early Phase 1 |
|
|
|
47 |
|
Katacalcin |
|
|
|
|
|
48 |
|
calcitonin |
|
|
|
|
|
49 |
|
Vasodilator Agents |
|
|
|
|
|
50 |
|
Caseins |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 53)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
12-months of Treatment With Burosumab in Children and Adolescents With X-linked Hypophosphatemia: a Prospective Longitudinal Cohort Study |
Recruiting |
NCT04419363 |
Phase 4 |
Burosumab Injection |
2 |
A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease |
Recruiting |
NCT03466983 |
Phase 4 |
Iron Isomaltoside;Ferric Carboxymaltose |
3 |
Comparing the Effectiveness of High or Low Dose of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia |
Recruiting |
NCT03820518 |
Phase 4 |
Calcitriol |
4 |
Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy |
Recruiting |
NCT04146935 |
Phase 4 |
Burosumab Injection [Crysvita] |
5 |
Hupophosphatemia Levels Deleteriously Affect Outcome of Patients With Severe Sepsis/Septic Shock Admitted to ICU |
Not yet recruiting |
NCT04519762 |
Phase 4 |
Glycophos (Sodium Glycerophosphate);Antibiotics;Inotropes |
6 |
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism |
Completed |
NCT00975000 |
Phase 3 |
Cinacalcet;Placebo |
7 |
The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH) |
Completed |
NCT00417612 |
Phase 3 |
Paricalcitol |
8 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02526160 |
Phase 3 |
|
9 |
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02537431 |
Phase 3 |
|
10 |
A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside/Ferric Derisomaltose and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (Phosphare-IDA-04) |
Completed |
NCT03238911 |
Phase 3 |
Iron isomaltoside/ferric derisomaltose;Ferric carboxymaltose |
11 |
A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside/Ferric Derisomaltose and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (Phosphare-IDA-05) |
Completed |
NCT03237065 |
Phase 3 |
Iron isomaltoside/ferric derisomaltose;Ferric carboxymaltose |
12 |
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH) |
Completed |
NCT02915705 |
Phase 3 |
Oral Phosphate Supplement;active vitamin D |
13 |
An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome(ENS) and Associated Hypophosphatemic Rickets |
Completed |
NCT03581591 |
Phase 3 |
|
14 |
An Investigator-sponsored Phase 3b Open-label Study of Anti- FGF23 Antibody Burosumab (KRN23) in Adult Patients With Xlinked Hypophosphatemia (XLH) in GERmany - BurGER |
Recruiting |
NCT04695860 |
Phase 3 |
Burosumab |
15 |
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH) |
Recruiting |
NCT03920072 |
Phase 3 |
Burosumab |
16 |
Oral Potassium Acid Phosphate Supplementation for Preterm Neonates; a Comparison of Oral Thin Films and Standard Oral Therapy. |
Unknown status |
NCT01676844 |
Phase 2 |
Oral thin film therapy (Potassium acid phosphate oral thin films);Standard therapy (Potassium acid phosphate oral solution) |
17 |
A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding |
Completed |
NCT01307007 |
Phase 2 |
Ferric Carboxymaltose (FCM);Iron Dextran Injection |
18 |
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02163577 |
Phase 2 |
|
19 |
A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia |
Completed |
NCT01340482 |
Phase 1, Phase 2 |
KRN23 |
20 |
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) |
Completed |
NCT02750618 |
Phase 2 |
|
21 |
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia |
Completed |
NCT01571596 |
Phase 1, Phase 2 |
KRN23 |
22 |
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) |
Completed |
NCT02312687 |
Phase 2 |
|
23 |
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH) |
Recruiting |
NCT04188964 |
Phase 1, Phase 2 |
Burosumab |
24 |
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia |
Completed |
NCT00830674 |
Phase 1 |
Placebo;KRN23 |
25 |
Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia |
Terminated |
NCT01748812 |
Phase 1 |
Osteomalacia |
26 |
Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma |
Terminated |
NCT00622479 |
Phase 1 |
Sorafenib (Nexavar, BAY43-9006) |
27 |
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant |
Unknown status |
NCT01011114 |
|
Cinacalcet;Placebo |
28 |
Hypophosphatemic Rickets in Norway |
Unknown status |
NCT01057186 |
|
Sevelamer |
29 |
Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia |
Unknown status |
NCT01660308 |
|
|
30 |
The Prevention of Refeeding Syndrome by a Diet Regime in Patient With Head and Neck Cancer |
Completed |
NCT01845922 |
|
|
31 |
Study of the Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus. |
Completed |
NCT01991574 |
Early Phase 1 |
Calcium acetate;Placebo |
32 |
X-linked Hypophosphatemia and Carbohydrate and Lipid Metabolism: a Role for FGF21? |
Completed |
NCT03596554 |
|
|
33 |
Evaluation of Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU |
Completed |
NCT03529058 |
|
|
34 |
Calcitonin for Treating X-linked Hypophosphatemia |
Completed |
NCT01652573 |
|
nasal salmon calcitonin;Saline Nasal Spray Placebo |
35 |
Hypophosphatemia in the ICU - A One-day Point Prevalence Survey |
Completed |
NCT04201899 |
|
|
36 |
Evaluation of Hypophosphatemia as a Predictor of Sepsis in Surgical Resuscitation Units. |
Completed |
NCT03740802 |
|
|
37 |
Hypophosphatemia Deleteriously Affects Outcome of Septic Shock Patients Admitted to ICU |
Completed |
NCT04455113 |
|
|
38 |
Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study |
Completed |
NCT00688077 |
|
Calcitonin;Placebo |
39 |
Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4 |
Completed |
NCT00764816 |
|
|
40 |
Dental Implants in Patients With X-linked Hypophosphatemia |
Recruiting |
NCT03879915 |
|
|
41 |
Calcitriol Monotherapy for X-Linked Hypophosphatemia: Effects on Mineral Ions, Growth and Skeletal Parameters |
Recruiting |
NCT03748966 |
Early Phase 1 |
Calcitriol |
42 |
Interplay of FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP) |
Recruiting |
NCT03489993 |
|
|
43 |
Characterising Pain, Quality of Life, Body Composition, Arterial Stiffness, Muscle Function, Bone Density and Geometry in Adult Persons With Hereditary Hypophosphatemia and Healthy Controls |
Recruiting |
NCT04273490 |
|
|
44 |
X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP) |
Recruiting |
NCT03651505 |
|
|
45 |
An International, Multicentre, Prospective, Non-interventional Observational Registry for Patients With X-linked Hypophosphatemia (XLH) |
Recruiting |
NCT03193476 |
|
|
46 |
The Impact of Phosphate Metabolism on Healthy Aging |
Recruiting |
NCT03771105 |
Early Phase 1 |
phosphate |
47 |
An International, Multicenter, Prospective, Longitudinal Observational Study for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia |
Recruiting |
NCT03745521 |
|
|
48 |
Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED Focused on the Prevention of RRT-related Hypophosphatemia and Optimization of Acid-base Balance: a Pilot Study |
Active, not recruiting |
NCT03976440 |
|
|
49 |
Retrospective and Prospective Disease Progression and Quality of Life in X-linked Hypophosphatemia (XLH) |
Active, not recruiting |
NCT04049877 |
|
|
50 |
An Open Label Trial to Assess the Safety and Efficacy of Burosumab in a Single Patient With Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) |
Active, not recruiting |
NCT03993821 |
Early Phase 1 |
Burosumab |
Inferred drug relations via
UMLS
71
/
NDF-RT
51
:
Dibasic potassium phosphate
dibasic sodium phosphate heptahydrate
Ergocalciferol
Monobasic potassium phosphate
potassium phosphate
POTASSIUM TRIPOLYPHOSPHATE
sodium phosphate
|
SODIUM PHOSPHATE DIHYDRATE
Sodium Phosphate, Dibasic
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Sodium Phosphate, Monobasic
SODIUM PHOSPHATE,MONOBASIC,MONOHYDRATE
SODIUM PHOSPHATE,TRIBASIC PWDR
Tribasic Sodium Phosphate
|
Cochrane evidence based reviews: hypophosphatemia
|